Drugs / ICC-1132
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00587249 | Jul 2002 → Jul 2005 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICC-1132 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00587249 ↗ |
| Known as | Malariavax | “ICC-1132 (Malariavax) is a recombinant, virus-like particle malaria vaccine comprised of hepatitis core antigen engineered to express the central repeat regions from Plasmodium...” PMID 18253503 ↗ Feb 2008 |
| Modality | Vaccine | “ICC-1132 (Malariavax) is a recombinant, virus-like particle malaria vaccine” PMID 18253503 ↗ Feb 2008 |
| Route | Intramuscular | “We assessed an Alhydrogel (aluminum hydroxide)-adjuvanted vaccine formulation at three ICC-1132 dose levels, each injected intramuscularly (1.0 mL) on study days 0, 56 and 168.” PMID 18253503 ↗ Feb 2008 |